etbx-061
Vaccineexperimental
Clinical trial activity
20 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
17
Phase 2
18
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2017 (NCT03167177)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 2
- Carcinoma, Hepatocellular · Phase 1/Phase 2
- Carcinoma, Merkel Cell · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Squamous Cell · Phase 1/Phase 2
- Carcinoma, Transitional Cell · Phase 1/Phase 2
- Chordoma · Phase 1/Phase 2
- Colonic Neoplasms · Phase 1
- Colorectal Neoplasms · Phase 1/Phase 2
- Lung Neoplasms · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Melanoma · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 2
- Prostatic Neoplasms · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1/Phase 2
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
Mechanism of action
- Mucin-1Immunity, active
MUC1 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- etbx-061
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03574649 | Phase 2 | Sep 30, 2018 | NantWorks |
| NCT03554109 | Phase 2 | Sep 30, 2018 | NantWorks |
| NCT03563144 | Phase 2 | Aug 31, 2018 | NantWorks |
| NCT03647423 | Phase 1/Phase 2 (Phase 2) | Aug 31, 2018 | NantWorks |
| NCT03586869 | Phase 1/Phase 2 (Phase 2) | Jul 28, 2018 | NantWorks |
| NCT03481816 | Phase 1 | Jul 24, 2018 | National Cancer Institute (NCI) |
| NCT03563157 | Phase 1/Phase 2 (Phase 2) | May 25, 2018 | NantWorks |
| NCT03563170 | Phase 1/Phase 2 (Phase 2) | May 25, 2018 | NantWorks |
| NCT03387085 | Phase 1/Phase 2 (Phase 2) | Mar 16, 2018 | NantWorks |
| NCT03384316 | Phase 1 | Jan 31, 2018 | National Cancer Institute (NCI) |
| NCT03387111 | Phase 1/Phase 2 (Phase 2) | Jan 13, 2018 | NantWorks |
| NCT03197571 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2017 | NantWorks |
| NCT03197584 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2017 | NantWorks |
| NCT03169777 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2017 | NantCell, Inc. |
| NCT03169764 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2017 | NantCell, Inc. |
| NCT03169738 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2017 | NantCell, Inc. |
| NCT03167177 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2017 | NantCell, Inc. |
| NCT03167164 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2017 | NantCell, Inc. |
| NCT03175666 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2017 | NantCell, Inc. |
| NCT03169790 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2017 | NantCell, Inc. |
Showing 20 of 20 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NantWorks | For profit | 11 | 11 | 1 | 2017 |
| NantCell, Inc. | For profit | 7 | 7 | 1 | 2017 |
| National Cancer Institute (NCI) | Government | 2 | 2 | 1 | 2018 |
3 organizations
Page 1 / 1